Living creatively

For small, early stage biotech companies, 2012 could be the year of living creatively.

Although public biotechs raised more funds last year than ever before, the vast majority of the money was debt financing by established companies with marketed products. Thus while the overall numbers look good and are likely to continue to do so, precommercial companies will have to get creative with their financings...